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We assessed overall and cause-speciﬁc mortality and risk factors for late mortality in a nation-wide popu-
lation-based cohort of 4547 adult cancer patients who survived 2 or more years after receiving an autologous
hematopoietic stem cell transplantation (HSCT) in Australia between 1992 and 2005. Deaths after HSCT were
identiﬁed from the Australasian Bone Marrow Transplant Recipient Registry and through data linkage with
the National Death Index. Overall, the survival probability was 56% at 10 years from HSCT, ranging from 34%
for patients with multiple myeloma to 90% for patients with testicular cancer. Mortality rates moved closer to
rates observed in the age- and sex-matched Australian general population over time but remained signiﬁ-
cantly increased 11 or more years from HSCT (standardized mortality ratio, 5.9). Although the proportion of
deaths from nonrelapse causes increased over time, relapse remained the most frequent cause of death for all
diagnoses, 10 or more years after autologous HSCT. Our ﬁndings show that prevention of disease recurrence
remains 1 of the greatest challenges for autologous HSCT recipients, while the increasing rates of nonrelapse
deaths due to the emergence of second cancers, circulatory diseases, and respiratory diseases highlight the
long-term health issues faced by adult survivors of autologous HSCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION small patient numbers, limited duration of follow-up, or
Hematopoietic stem cell transplantation (HSCT) provides
a favorable treatment outcome for several adult and child-
hood cancers. Autologous HSCT is used to treat a growing
number of adult patients with malignancies each year,
particularly older patients. In Australia, over two thirds of all
HSCTs are autologous transplantations, with more than one
half of these in patients treated for non-Hodgkin lymphoma
and multiple myeloma [1].
Although long-term survival has been studied extensively
in allogeneic HSCT recipients [2-4], few studies have char-
acterized the long-term risk of death after autologous HSCT.
Although rates of treatment-related mortality are consider-
ably lower among autologous recipients compared with
allogeneic transplantation recipients, overall mortality is
higher than the general population, with the leading causes
of late deaths being relapse or progressive disease and sec-
ond cancers [5-10].
Previous studies examining late mortality in adult re-
cipients of autologous HSCT have largely been carried out as
single or multicenter hospital-based studies, often withdgments on page 944.
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comorbid health conditions in older patients who have un-
dergone autologous HSCT places them at increased risk of
other potentially fatal health conditions. Previously, we re-
ported the annual mortality rates in 1448 patients who had
survived 5 years or more after receiving an autologous HSCT
for acute myeloid leukemia or lymphoma in Australia or New
Zealand [7]. In this study, we examined overall and cause-
speciﬁc mortality and risk factors for late mortality in a
nation-wide population-based cohort of 4547 adult cancer
patients who survived 2 or more years after receiving an
autologous HSCT in Australia between 1992 and 2005.METHODS
Study Population
The Cancer after Stem Cell Transplantation study is an Australian
population-based cohort study examining long-term outcomes in recipients
of HSCT. Transplant recipients were identiﬁed from the Australasian Bone
Marrow Transplant Recipient Registry (ABMTRR), which records 99.5% of
HSCTs performed in Australia since 1992 and follows registrants on an
annual basis for vital status and disease recurrence.
Patients treated by autologous HSCT between 1992 and 2005 with a
primary diagnosis of acute lymphoblastic leukemia (ALL), acute myeloid
leukemia (AML), chronic myeloid leukemia (CML), non-Hodgkin lymphoma
(NHL), Hodgkin lymphoma (HL), multiple myeloma (MM), breast cancer, or
testicular cancer were considered. Patients ages 15 years or older who were
alive at least 2 years after HSCT were included in our analyses. Ethical
approval was obtained and the requirement for informed participant con-
sent was waived because the researchers received only deidentiﬁed data.Transplantation.
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and medical records held at HSCT units across Australia. Vital status and
cause of death were obtained by linking ABMTRR records with the Austra-
lian National Death Index (NDI). Patient’s name code (ﬁrst 2 letters of given
name and ﬁrst 4 letters of surname), sex, date of birth, date of death, and
state of residence were used during record linkage that was performed
utilizing an established probabilistic algorithm. A linkage probability or
weight was given to each potential matching record pair, and a subset of
paired records underwent clerical review. Patients who did not link with the
NDI but who were recorded as deceased in medical records or the ABMTRR
were classiﬁed as deceased in our analyses (8.6% of all deaths).
Causes of death were identiﬁed from the underlying cause of death
recorded on the NDI, using the ICD-9 classiﬁcation for deaths registered
before 1997 and the ICD-10 classiﬁcation for deaths registered from 1997 on.
Causes of death were categorized as relapse or progression of the primary
diagnosis (C00-C97, corresponding to the primary diagnosis); second ma-
lignant neoplasm (C00-C97/D46, except the primary diagnosis); diseases of
the circulatory system (I00-I99); diseases of the respiratory system (J00-
J99); external, nonmedical causes (V01-Y98, excluding Y40-Y84); or other
medical causes (all remaining deaths including cancers diagnosed before the
primary diagnosis).Statistical Analyses
All analyses were performed using STATA, Version 12 (StataCorp, TX).
Overall survival probabilities were estimated by the Kaplan-Meier method.
Survival probabilities were calculated from the date of HSCT to the date of
death or date of censoring (December 31, 2007) for those who remained
alive. Cause-speciﬁc probabilities of death after HSCT were calculated using
cumulative incidence estimates, treating deaths from known causes as
competing risks and excluding deaths from unknown causes.
Relative survival ratios (RSRs), the ratio of observed overall survival in
the study population to expected overall survival in the general AustralianTable 1
Characteristics of Australian Adult Autologous HSCT Recipients, 1992-2005, Surviv
Characteristic Total Cohort Primary Diagnosis
NHL MM HL
No. of patients 4547 1765 1613 442
Median follow-up, yr 4.94 5.19 4.15 5.86
Transplantation type
Single 4041 1742 1466 425
Staged 506 23 147 17
Sex
Male 2566 1116 982 256
Female 1981 649 631 186
Age at HSCT, yr
15-29 399 111 5 175
30-44 1024 420 150 189
45-59 2122 894 850 71
60þ 1002 340 608 7









BM 203 78 32 38
PB 4183 1634 1567 377
BM and PB 159 52 14 26
Transplantation era
1992-1994 442 152 58 60
1995-1997 849 332 167 104
1998-2000 997 363 355 80
2001-2003 1245 505 551 111
2004-2005 1014 413 482 87
Received subsequent
transplantation*
Yes 536 167 276 43
No 4011 1598 1337 399
Relapsed <2 years from
HSCT
Yes 1126 371 497 84
No 3421 1394 1116 358
Deaths 1466 454 627 92










ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, c
NHL, non-Hodgkin lymphoma; BM, bone marrow; PB, peripheral blood; HSCT, hem
* Received subsequent transplantation within 2 years of ﬁrst transplantation.population, were calculated using the Ederer II method [11]. Expected sur-
vival rates were generated from Australian population life tables for 1992 to
2007, stratiﬁed by age and sex.
Standardizedmortality ratios (SMRs), the ratio of deaths observed in the
study population to deaths expected in the Australian general population,
were generated for deaths from any cause. Rates of expected deaths were
calculated bymultiplying the number of person years at risk in each age, sex,
state, and calendar year band by the corresponding Australian mortality
rates reported by the NDI. Person years at risk were calculated from 2 years
after the date of HSCT to the date of death or date of censoring (December 31,
2007) for those who remained alive. Cause-speciﬁc SMRs were calculated
for deaths from second malignant neoplasms (excluding deaths from mye-
lodysplastic syndromes in this analysis), diseases of the circulatory system,
and diseases of the respiratory system using the corresponding Australian
population mortality rates.
Risk factor analysis by primary diagnosis (AML, MM, NHL, HL, or breast
cancer) was conducted using multivariate Cox regression models for overall
mortality, and competing risk regression models for relapse and nonrelapse
mortality. Multivariable model building with covariates age (<45 years
versus  45 years), sex, transplantation era (<2000 versus  2000), and
stem cell source (peripheral blood versus bone marrow or bone marrow and
peripheral blood) was performed using methods described by Bursac et al.
[12]. For each covariate, the proportional hazards assumption was tested
using a time varying covariate. The probability level for statistically signif-
icance was set at .05.
RESULTS
Patient Characteristics
From 1992 to 2005, 6699 adult cancer patients ages
15 years or older were treated by autologous HSCT for ALL,
AML, HL, NHL, CML, MM, breast cancer, or testicular cancer.ing at Least Two Years after HSCT
AML ALL CML Breast Testicular
208 49 44 378 48
8.15 8.09 4.94 7.91 7.58
203 48 44 90 23
5 1 0 288 25
110 27 27 0 48
98 22 17 378 0
41 25 1 12 29
50 10 11 180 14
83 10 25 184 5












40 6 4 1 4
119 39 38 371 38
49 4 2 6 6
61 12 11 80 8
43 8 13 174 8
46 11 9 117 16
38 13 10 7 10
20 5 1 0 6
25 7 11 7 0
183 42 33 371 48
37 12 20 100 5
171 37 24 278 43












hronic myeloid leukemia; MM, multiple myeloma; HL, Hodgkin lymphoma;
atopoietic stem cell transplantation.
Figure 1. Overall survival probabilities by primary diagnosis of Australian
adult autologous HSCT recipients, 1992-2005, surviving at least 2 years after
HSCT.
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and were included in our analyses. The median age at
transplantationwas 51.5 (range, 15.0 to 79.2) years, 56% were
male, and the median duration of follow-up from 2 year after
transplantationwas 4.94 (range, 2.00 to 16.0) years (Table 1).Overall Mortality
A total of 1466 (32.2%) deaths were observed. At 5 years
from HSCT, the overall survival probabilities were 74.1% for
the entire cohort, 79.4% for NHL, 65.6% for MM, 83.0% for HL,
84.3% for AML, 80.9% for ALL, 60.1% for CML, 65.6% for breast
cancer, and 93.0% for testicular cancer (Figure 1). At 10 years
from HSCT, the overall survival probabilities were 56.3% for
the entire cohort, 64.5% for NHL, 34.2% for MM, 74.6% for HL,
76.1% for AML, 75.1% for ALL, 54.1% for CML, 47.1% for breast
cancer, and 90.0% for testicular cancer. The overall survival at
5 years and 10 years for all patients with a hematological
primary disease was 74.8% and 57.1% respectively.Overall Survival Relative to the General Population
(Relative Survival Ratios)
In the interval of 2 to 5 years from HSCT, RSRs by primary
diagnosis ranged from .54 (95% conﬁdence interval [CI], .375
to .68) for CML to .91 (95% CI, .77 to .97) for testicular cancer
(Table 2). For the interval of 6 to 10 years from HSCT,
observed survival approached expected survival for all pri-
mary diagnoses. During this period the observed rates of
survival in patients with ALL and CML were similar to those
observed in the general population, while the RSR for MMTable 2
Interval Speciﬁc Relative Survival Ratios by Primary Diagnosis and Disease Status a
Primary diagnosis 2-5 Years from HSCT
RSR* 95% CI







Breast cancer .600 .547-.647
Testicular cancer .909 .768-.968
All hematological malignancies .718 .702-.733
Relapse <2 yr .374 .343-.405
Disease-free at 2 yr .828 .813-.843
HSCT indicates hematopoietic stem cell transplantation; RSR, relative survival rati
* The ratio of observed to expected overall survival in the age- and sex-matchedimproved by only 2% from 2 to 5 years (RSR, .61; 95% CI, .59 to
.64) to 6 to 10 years from HSCT (RSR, .63; 95% CI, .57 to .69).
Cumulative relative survival ratios at 5 years and 10 years
from HSCT are provided in Supplementary Table 1.
RSRs continued to increase for breast cancer, HL, MM, and
NHL 11 or more years from HSCT, whereas RSRs for AML and
ALL decreased. Across all time periods, RSRs were over .80 for
patients disease-free at 2 years, with observed survival
improving to within 8% of expected survival beyond 11 years
fromHSCT (RSR, .92; 95% CI, .88 to .96). RSRs for patients who
had relapsedwithin 2 years of HSCTwere below .80 across all
time periods, increasing from .37 (95% CI, .34 to .41) during 2
to 5 years from HSCT to .75 (95% CI, .51 to .89) beyond
11 years (Table 2).Risk of Death from Any Cause Relative to General
Population
Overall, 15 times more deaths occurred in the study
population than expected in the age-, sex-, and calendar
yearematched Australian general population (SMR, 15.01;
95% CI, 14.26 to 15.80) (Table 3). Observed mortality was
greater than expected for both sexes. However, the SMR for
females (SMR, 20.75; 95% CI,19.22 to 22.40) was almost twice
that of males (SMR, 12.28; 95% CI, 11.46 to 13.15). SMRs
decreased with increasing age at HSCT, with almost 36 times
more deaths than expected in patients ages 15 to 29 years at
HSCT (SMR, 35.89; 95% CI, 28.44 to 45.29) and almost 9 times
more deaths than expected in patients aged 60 or older at
HSCT (SMR, 8.55; 95% CI, 7.73 to 9.46). SMRs were greater
than 1.00 for all primary diagnoses, ranging from7.29 (95% CI,
5.53 to 9.62) for AML to 37.18 (95% CI, 32.44 to 42.60) for
breast cancer. Observed mortality for patients who had
relapsed within 2 years of HSCT was 45 times greater than
expected (SMR, 45.42; 95% CI, 42.18 to 48.90), whereas pa-
tients who remained disease-free in the same interval had a
moremodest increase inmortality (SMR, 9.29; 95% CI, 8.65 to
9.97). Although rates of observed mortality moved closer to
rates of expected mortality with increasing years from HSCT,
observed mortality remained greater than expected beyond
10 years from HSCT (SMR, 5.92; 95% CI, 4.16 to 8.41). Overall,
observed mortality ranged from 12 to 16 times greater than
expected across all transplantation eras and stem cell sources.Within-cohort Risk of Death from Any Cause
Patients with AML, NHL, and MMwhowere ages 45 years
or older at transplantationwere twice as likely to die as thoset Two Years
6-10 Years from HSCT 11þ Years from HSCT
RSR* 95% CI RSR* 95% CI
.803 .779-.825 .910 .866-.943
.837 .800-.869 .906 .826-.956
.634 .571-.691 .837 .611-.953
.901 .840-.940 .962 .830-.999
.930 .855-.972 .917 .760-.984
.958 .695-1.002 .851 .306-.982
.941 .566-1.011 e e
.746 .675-.804 .896 .766-.961
e e e e
.808 .782-.832 .911 .860-.947
.618 .538-.690 .748 .505-.892
.830 .805-.852 .924 .880-.956
o; e no deaths occurred in interval.
general population of Australia.
Table 3
SMRs for Autologous HSCT Recipients, 1992-2005, Ages Over 15 yr, Surviving at Least Two Years after HSCT
Characteristic All Patients Second Malignancies* Circulatory Diseases Respiratory Diseases
n No of
Deaths
SMR (95% CI) No of
Deaths
SMR (95% CI) No of
Deaths
SMR (95% CI) No of
Deaths
SMR (95% CI)
Overall 4547 1466 15.01 (14.26-15.80) 100 2.35 (1.94-2.86) 56 2.31 (1.78-3.00) 16 2.61 (1.60-4.26)
Sex
Male 2566 812 12.28 (11.46-13.15) 67 2.48 (1.96-3.16) 37 2.05 (1.49-2.83) 6 1.50 (.67-3.34)
Female 1981 654 21.75 (19.22-22.40) 33 2.13 (1.51-3.00) 19 3.06 (1.95-4.80) 10 4.71 (2.53-8.74)
Age at HSCT, yr
15-29 399 71 35.89 (28.44-45.29) 5 21.0 (8.71-50.3) 1 5.89 (.83-41.8) 0 -
30-44 1024 286 31.27 (27.85-35.12) 19 5.74 (3.67-9.00) 9 5.26 (2.74-10.1) 2 7.74 (1.94-30.9)
45-60 2122 734 17.20 (16.00-18.50) 44 2.15 (1.60-2.89) 28 2.82 (1.51-4.08) 8 3.54 (1.77-7.09)
60 1002 375 8.55 (7.73-9.46) 32 1.73 (1.22-2.45) 18 1.45 (0.91-2.30) 6 1.68 (0.75-3.74)
Primary diagnosis
NHL 1765 454 11.00 (10.04-12.06) 46 2.58 (1.94-3.45) 27 2.55 (1.75-3.72) 9 3.50 (1.82-6.72)
MM 1613 627 16.56 (15.31-17.91) 25 1.50 (1.02-2.23) 18 1.83 (1.15-2.90) 5 1.94 (0.81-4.67)
HL 442 92 22.37 (18.24-27.45) 10 6.89 (3.71-12.8) 3 3.53 (1.14-10.9) 0 -
AML 208 50 7.29 (5.53-9.62) 5 1.72 (0.72-4.13) 1 0.60 (0.08-4.25) 2 4.69 (1.17-18.8)
ALL 49 12 21.67 (12.31-38.16) 3 14.4 (4.63-44.5) 0 - 0 -
CML 44 20 20.50 (13.23-31.78) 2 4.52 (1.13-18.1) 1 4.16 (0.59-29.5) 0 -
Breast cancer 378 207 37.18 (32.44-42.60) 8 2.68 (1.32-5.27) 6 6.88 (3.09-15.3) 0 -
Testicular cancer 48 4 8.70 (3.27-23.18) 1 10.3 (1.45-72.9) 0 - 2 4.77 (1.19-19.1)
Relapsed <2 years from
HSCT
Yes 1126 703 45.42 (42.18-48.90) 15 2.28 (1.37-3.78) 17 4.41 (2.74-7.09) 6 6.30 (2.83-14.0)
No 3421 763 9.29 (8.65-9.97) 85 2.37 (1.91-2.99) 39 1.91 (1.40-2.62) 0 -
Years from HSCT
2-5 4547 1151 17.85 (16.85-18.91) 60 2.16 (1.67-2.78) 37 2.29 (1.66-3.16) 12 3.00 (1.70-5.28)
6-10 1797 284 10.17 (9.05-11.42) 34 2.76 (1.97-3.87) 14 2.04 (1.21-3.45) 1 0.56 (0.08-3.96)
11þ 524 31 5.91 (4.16-8.41) 6 2.55 (1.15-5.67) 5 4.09 (1.70-9.83) 3 8.94 (2.88-27.7)
Transplantation era
1992-1994 442 213 14.84 (12.97-16.97) 16 2.61 (1.60-4.27) 13 3.74 (2.17-6.44) 4 4.84 (1.82-12.9)
1995-1997 849 403 16.42 (14.89-18.10) 35 3.30 (2.37-4.59) 13 2.19 (1.27-3.77) 3 2.10 (0.68-6.51)
1998-2000 997 421 15.27 (13.88-16.80) 24 2.00 (1.34-2.98) 18 2.54 (1.60-4.02) 2 1.10 (0.27-4.39)
2001-2003 1245 350 14.13 (12.73-15.69) 19 1.74 (1.11-2.73) 10 1.61 (0.87-3.00) 5 3.06 (1.28-7.36)
2004-2005 1014 79 12.34 (9.90-15.38) 6 2.12 (0.95-4.73) 2 1.34 (0.33-5.35) 10 1.93 (1.04-3.59)
Stem cell source
BM 203 79 12.64 (10.14-15.76) 7 2.76 (1.32-5.79) 6 4.10 (1.84-9.12) 1 2.92 (0.41-20.7)
PB 4183 1319 15.24 (14.43-16.08) 84 2.22 (1.79-2.75) 49 2.27 (1.71-3.00) 15 2.72 (1.64-4.51)
BM þ PB 159 67 14.00 (11.02-17.78) 9 4.34 (2.26-8.33) 0 - 0 -
Subsequent transplantation
Yes 536 281 32.91 (29.28-36.99) 16 4.42 (2.71-7.22) 7 3.37 (1.61-7.08) 3 6.48 (2.09-20.1)
No 4011 1185 13.30 (12.56-14.08) 84 2.16 (1.75-2.68) 49 2.21 (1.67-2.93) 13 2.30 (1.33-3.95)
BM indicates bone marrow; PB, peripheral blood; HSCT, hematopoietic stem cell transplantation; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; HL,
Hodgkin lymphoma; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CI, conﬁdence interval; SMR, stan-
dardized mortality ratios.
* Deaths from new malignancy, excludes deaths from myelodysplastic syndromes as populations rates for deaths from malignant neoplasms do not include
deaths from myelodysplastic syndromes.
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were over 50% less likely to die compared to males with AML
(hazard ratio [HR], .43; 95% CI, .23 to .79; P ¼ .007). However,
sex did not appear to effect the risk of death for any of the
other primary diagnoses (P > .05), indicating that this un-
expected association requires further examination in a larger
patient cohort. Although a more recent transplantation era
appeared to have a weak association with improved survival
for patients with AML, MM, and HL, its inﬂuence only
reached signiﬁcance for NHL patients who underwent
transplantation after the year 2000; they were 20% less likely
to die compared with those who underwent transplantation
before the year 2000 (HR, .79; 95% CI, .64 to .97). Stem cell
source appeared to inﬂuence survival in patients with HL,
where those who underwent transplantation with cells from
peripheral blood were 40% less likely to die compared with
those who underwent transplantation with cells from bone
marrow or peripheral blood plus bone marrow (HR, .57; 95%
CI, .36 to .90; P ¼ .016). In univariate analyses, none of the
characteristics examined were signiﬁcantly associated with
survival after HSCT for breast cancer (P > .05).Cause-speciﬁc Mortality
The majority of deaths occurred from relapse or pro-
gressive disease (73.0%), followed by second malignant
neoplasms (7.5%), diseases of the circulatory system (4.8%),
and diseases of the respiratory system (1.1%) (Supplementary
Table 2). The distribution of cause of death was similar when
only examining individuals who underwent transplantation
for a hematological malignancy (data not shown). Overall,
the most common second malignancy causing death was
AML. Other medical causes accounted for 4.0% of deaths,
whereas external, nonmedical causes accounted for .9% of
deaths. The underlying cause of death was unknown for 141
(9.6%) patients, 15 of whom had no underlying cause of death
recorded on the NDI, and 126 were recorded as deceased on
the ABMTRR but did not link with a record on the NDI.
Relapse or progressive disease remained the most com-
mon cause of death 11 or more years after HSCT. However,
the proportion of deaths attributable to nonrelapse causes
increased with increasing time from HSCT (Supplementary
Table 3). At 5 years from HSCT, the cumulative incidence of
deaths from relapse or progressive disease was 14-fold
Table 4





P Value Relapse Deaths HR
(95% CI)
P Value Nonrelapse Deaths HR
(95% CI)
P Value
NHL (n ¼ 300 relapse, n ¼ 115 nonrelapse deaths)
Age*,y,z
<45 yr 1.00 - 1.00 - 1.00 -
45 yr 2.22 (1.77-2.79) < .001 2.32 (1.73-3.11) < .001 1.88 (1.21-2.91) .004
Sex
Male 1.00 - 1.00 - 1.00 -
Female .91 (.75-1.11) .364 .99 (.78-1.25) .902 .78 (.53-1.16) .215
Transplantation era*,y
<2000 1.00 - 1.00 1.00 -
2000 .79 (.64-.97) .026 .71 (.55-.91) .007 .90 (.61-1.33) .594
MM (n ¼ 489 relapse, n ¼ 77 nonrelapse deaths)
Age*,y,z
<45 yr 1.00 - 1.00 - 1.00 -
45 yr 1.98 (1.46-2.70) < .001 1.75 (1.26-2.44) .001 4.96 (1.21-20.37) .026
Sex*,z
Male 1.00 - 1.00 - 1.00 -
Female .86 (.73-1.02) .082 .93 (.77-1.11) .410 .59 (.36-.98) .042
Transplantation eray
<2000 1.00 - 1.00 - 1.00 -
2000 .88 (.75-1.05) .158 .75 (.63-.91) .003 1.12 (.71-1.76) .629
HL (n ¼ 65 relapse, n ¼ 20 nonrelapse deaths)
Agez
<45 yr 1.00 - 1.00 - 1.00 .082
45 yr .95 (.55-1.65) .854 .81 (.40-1.66) .570 2.32 (.90-6.00)
Sex
Male 1.00 - 1.00 - 1.00 -
Female .77 (.50-1.18) .225 .68 (.41-1.14) .143 .86 (.34-2.14) .746
Transplantation eray
<2000 1.00 - 1.00 - 1.00 -
2000 .67 (.40-1.12) .126 .53 (.29-.96) .036 1.10 (.43-2.80) .858
Stem cell source*,y
BM or PB þ BM 1.00 - 1.00 - 1.00 -
PB .57 (.36-.90) .016 .61 (.35-1.06) .080 .69 (.28-1.71) .418
AML (n ¼ 31 relapse, n ¼ 13 nonrelapse deaths)
Age*,y
<45 yr 1.00 - 1.00 - 1.00 -
45 yr 2.08 (1.11-3.85) .020 2.02 (.93-4.37) .075 1.88 (.55-6.35) .311
Sex*,y
Male 1.00 - 1.00 - 1.00 -
Female .43 (.23-.79) .007 .44 (.21-.95) .036 .57 (.16-1.98) .376
Transplantation eraz
<2000 1.00 - 1.00 - 1.00 -
2000 1.63 (.84-3.17) .146 .19 (.52-2.68) .683 1.85 (.62-5.48) .269
BM indicates bone marrow; PB, peripheral blood; CI, conﬁdence interval; HR, hazard ratio; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; HL, Hodgkin
lymphoma; AML, acute myelogenous leukemia.
* Variable(s) adjusted for in Cox regression models for all deaths in each diagnosis group.
y Variable(s) adjusted for in competing risk regression models for relapse deaths in each diagnosis group.
z Variable(s) adjusted for in competing risk regression models for nonrelapse deaths in each diagnosis group.
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19.8% (Figure 2A). Although the cumulative incidence of
deaths from relapse increased by 1.5-fold from 5 to 10 years
after HSCT, the cumulative incidence of deaths from second
malignancies, circulatory diseases, other medical causes, and
external, nonmedical causes increased by 2-fold or greater
over the same period (Figure 2B). Beyond 10 years from
HSCT, the cumulative incidence of deaths from relapse began
to plateau (32.9% to 35.9%), whereas the cumulative inci-
dence of deaths from all other causes continued to increase
more sharply (Figure 2A).
Risk of Cause-speciﬁc Death Relative to the General
Population
Overall, the observed rates of death from each cause
examined were more than twice that expected based on
those in the general population (Table 3). For males, the risk
of death was increased for second malignancies (SMR, 2.48;
95% CI, 1.96 to 3.16) and circulatory diseases (SMR, 2.05; 95%
CI, 1.49 to 2.83) but not for respiratory diseases (SMR, 1.50;95% CI, .67 to 3.34), whereas for females, the risk of deathwas
elevated for each cause of death examined.
SMRs for deaths from second malignancies decreased
with increasing age at HSCT, with patients ages 15 to 29 years
at 20-fold excess risk. Although deaths from circulatory
diseases were elevated for patients from 30 to 44 years old
(SMR, 5.26; 95% CI, 2.74 to 10.12) and 45 to 59 years old (SMR,
2.82; 95% CI, 1.51 to 4.08), no excess risk was observed for
patients ages 15 to 29 years or  60 years at HSCT. Deaths
from respiratory diseases were also greater than expected for
patients from 30 to 44 and 45 to 59 years only (Table 3).
Deaths from second malignancies were greater than ex-
pected for all primary diagnoses apart for AML. SMRs ranged
from 1.50 (95% CI, 1.02 to 2.23) for patients with MM to 14.35
(95% CI, 4.63 to 44.50) for patients with ALL. Deaths from
circulatory diseases were signiﬁcantly increased for patients
with breast cancer, HL, MM, and NHL, whereas deaths from
respiratory diseases were signiﬁcantly increased for patients
with AML and NHL. The risk of death from second malig-
nancies remained high throughout the study. However,
Figure 2. (A) Shows cumulative incidence of death from relapse and nonrelapse causes. (B) Shows cumulative incidence of death from nonrelapse causes.
L.J. Ashton et al. / Biol Blood Marrow Transplant 20 (2014) 937e945942observed deaths from circulatory and respiratory diseases
were highest 11 or more years after HSCT.
Deaths from second malignancies were greater than ex-
pected for transplantations between 1992 and 2003. How-
ever, for patients who underwent transplantation from 2004
to 2005, deaths from second malignancies were not signiﬁ-
cantly increased (SMR, 2.09; 95% CI, .94 to 4.65). Deaths from
circulatory diseases were greater than expected for patients
who underwent transplantation between 1992 and 2000,
whereas deaths from respiratory diseases were elevated for
patients who underwent transplantation from 1992 to 1994
and 2001 to 2005. Deaths from each cause were greater than
expected regardless of disease status at 2 years from HSCT or
the number of transplants received.Within-cohort Risk of Cause-speciﬁc Death
Results for the analysis of potential risk factors for relapse
or nonrelapse related deaths within individual diagnosis
groups are shown in Table 4. Females with AML were at least
50% less likely to die from relapse compared with males with
AML (HR, .44; 95% CI, .21 to .95; P ¼ .036), whereas neither
age, sex, or transplantation era was associated with risk of
nonrelapse related death (P > .05). For patients with NHL,
those ages 45 years or older at transplantation were twice as
likely to die from relapse or nonrelapse causes as those ages
less than 45 years (HR, 2.32; 95% CI, 1.73 to 3.11; P .001; and
HR, 1.88; 95% CI, 1.21 to 2.91; P ¼ .004). However, patients
with NHL who underwent transplantation after 2000 were
30% less likely to die from relapse than thosewho underwent
transplantation before 2000 (HR, .71; 95% CI, .55 to .91;
P ¼ .007), whereas transplantation era and sex did not effectthe risk of dying from nonrelapse-related causes in this
patient group (P > .05). Patients with MM ages 45 years or
older were also more likely to die from either relapse or
nonrelapse-related causes compared with those ages
< 45 years at transplantation (P ¼ .026), whereas those who
underwent transplantation after the year 2000 were 25% less
likely to die of relapse compared with MM patients who
underwent transplantation before 2000 (HR, .75; 95% CI, .63
to .91; P ¼ .003). Neither age at transplantation nor sex were
associated with risk of relapse or nonrelapse-related deaths
in patients with HL (P > .05). However, the risk of relapse-
related death was signiﬁcantly reduced in HL patients
receiving a transplant after the year 2000 (HR, .53; 95% CI, .29
to .96; P¼ .036). No factors tested in univariate analysis were
found to be associated with relapse or nonrelapse deaths for
patients with breast cancer.DISCUSSION
We characterized the risk and causes of late mortality in
an Australian cohort of 4547 hematological and solid cancer
patients who survived for 2 or more years after autologous
HSCT. To our knowledge, this is the largest population-based
study of its kind reported to date and provides a compre-
hensive overview of survival among adult cancer recipients
of autologous HSCT. Among those who survived the ﬁrst
2 years after autologous HSCT, 76% remained alive at 5 years
and 59% were alive at 10 years. Survival rates were lower
than expected based on rates observed in the general pop-
ulation, and they were poorest among patients treated for
MM and breast cancer at 10 years. Overall, relapse or pro-
gression of disease was the most frequent cause of death,
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most common cause of death, and 26% of these were AML.
Although the proportion of deaths from nonrelapse causes
increased over time since HSCT, relapse remained the most
frequent cause of death 10 or more years after autologous
HSCT.
For all primary cancer diagnoses, observed rates of sur-
vival were below those expected based on rates in the age-
and sex-matched general population. Although observed
survival moved closer to expected survival with increasing
time from HSCT, survival continued to remain less than ex-
pected beyond 10 years from HSCT. As with previous studies,
we found that the cumulative incidence of death from
relapse appeared to plateau 10 or more years after autolo-
gous HSCT, whereas the cumulative incidence of death from
nonrelapse causes continued to rise steadily [5,7,9].
The rates of death from second cancers, circulatory dis-
eases, and respiratory diseases were all over 2 times greater
than rates observed in the general population. Although
increased risks of death from second cancer have been
consistently reported in other studies of autologous HSCT
survivors [5-7,13-15], few studies have reported on late
mortality due to circulatory or respiratory diseases. We
observed increased rates of death from circulatory diseases
in patients treated for HL, MM, and NHL, with the highest
rates observed among patients treated for breast cancer,
whereas increased rates of death due to respiratory diseases
were observed among those who underwent transplantation
for NHL and AML. The causes of cardiovascular and pulmo-
nary disease after HSCT are likely to be multifactorial.
Nevertheless, our ﬁndings are consistent with a recent study
of cardiovascular outcomes in 2-year survivors of autologous
and allogeneic HSCT that reported a 3.6-fold increased risk of
cardiovascular death compared with the general population
[16] and the Bone Marrow Transplant Survivor Study
(BMTSS), which showed an increased risk of late deaths due
to cardiac complications in females and an increased risk of
late death due to pulmonary dysfunction among males and
HL survivors [5]. Unlike our study, the BMTSS also included
pediatric HSCT recipients. Hence, it is not surprising that the
risk of late deaths due to circulatory and pulmonary disease
was more apparent in different diagnosis groups in our
study, as older cancer patients carry a greater burden of co-
morbid conditions, such as hypertension and diabetes.
Nevertheless, with increased follow-up of our cohort, the
pattern of causes of death is likely to change over time and
the number of deaths due to cardiovascular and pulmonary
disease, as well as second cancers, will continue to increase.
Older age at transplantation was a common risk factor for
overall mortality among primary diagnosis groups and was
also associated with an increased risk of relapse and non-
relapse mortality for patients with NHL and MM. These
ﬁndings are consistent with previous studies reporting that
older patients have poorer survival outcomes after autolo-
gous HSCT [5,7,10,17]. For NHL, MM, and HL, later trans-
plantation era was associated with a reduced risk of
mortality from relapse, indicating an improvement in the
effectiveness of treatment protocols over time for these he-
matological malignancies. The BMTSS has reported increased
risk of nonrelapse mortality in children and adult patients
who received peripheral blood stem cells [5]. However, we
were unable to detect an association between stem cell
source and overall mortality for most primary diagnosis
groups in our study. Although HL patients receiving periph-
eral blood stem cells were 40% more likely to survive, stemcell source did not appear to be associated an increased the
risk of relapse or nonrelapse death in our cohort.
A limitation of our study is that we were unable to
discriminate between anthracycline-associated congestive
heart failure, radiation-induced coronary artery disease, and
other treatment-related exposures that may have occurred
before autologous HSCT. Nevertheless, previous studies have
reported autologous HSCT survivors to be at a greater risk of
coronary artery disease and cerebrovascular disease [18] or
display risk factors for congestive heart failure, such as low
levels of high-density lipoprotein cholesterol or hyperten-
sion [16,19,20], which may have contributed to the increased
risk of cardiovascular death observed in our cohort.
Although autologous HSCT is no longer a common treat-
ment option for breast cancer, the high risk of cardiovascular
death among patients treated for breast cancer in our study
is consistent with previous reports of increased cardiovas-
cular death in breast cancer patients treated with adjuvant
radiotherapy [21]. Advances in conditioning regimens and
prophylaxis for infection may also have altered the risk of
late mortality due to pulmonary complications after autolo-
gous HSCT. Although we did not collect speciﬁc data on post-
transplantation infections or comorbid conditions, such as
asthma, the increased risk of death attributed to respiratory
disease is consistent with a recent report from 1243 adult
HSCT recipients showing that pulmonary complications
occurring after autologous HSCT effect survival [22].
Although transplantation era can be used as a surrogate in-
dicator for changes in treatment protocols or supportive care
over time, we were unable to fully assess mortality risk
associated with particular types of cancer or transplantation-
related treatments. Further analysis of factors such as con-
ditioning protocols, prophylaxis, and pretransplantation
therapies is required for a more comprehensive assessment
of treatment speciﬁc late mortality.
Unlike most previous studies, we minimized bias and
maximized the completeness of our mortality data by
ascertaining deaths via population based data linkage of
transplant records with the NDI. Despite this, the use of a
4  2 name code rather than full name information to link
records may have resulted in some error in record linkage.
Around 10% of patients had an unknown underlying cause of
death and were excluded from the cause-speciﬁc analyses.
Most of these patients were recorded on the ABMTRR as
deceased but did not link to the NDI. It is not inconceivable
that somewomen may have changed their names because of
marriage after HSCT, whereas delayed reporting of cause of
death to the NDI in 2007 may have resulted in missing data
relating to cause of death in the ﬁnal year of our analyses.
Misclassiﬁcation of the primary cause of death based on
the underlying cause of death recorded on death certiﬁcates
can occur, particularly in multimorbid individuals, resulting
in over- or under-estimated cause-speciﬁc results [6,23]. Our
cause-speciﬁc results may be limited to some extent by the
use of the underlying cause of death to measure chronic
disease mortality, as this may not fully account for comor-
bidity for other diseases. Although the impact of this issue on
the quality of cause of death reporting for cancer and other
chronic diseases is likely to be small in recipients of autolo-
gous HSCTs, some error may have been introduced when
distinguishing second malignancy deaths from relapse
deaths.
This is the largest population based study to date exam-
ining long-term survival outcomes that extend beyond
10 years in recipients of autologous HSCT. Cancer patients
L.J. Ashton et al. / Biol Blood Marrow Transplant 20 (2014) 937e945944who survived for at least 2 years after autologous HSCT
without recurrence of their original disease had a high
probability of surviving for more than 11 years. However, life
expectancy was not fully restored to levels seen in the gen-
eral Australian population. With the majority of deaths
occurring from relapse, prevention of disease recurrence
remains the greatest challenge for autologous HSCT re-
cipients. Strategies for preventing deaths from relapse, such
as transplantation earlier in the disease course and in those
who are in complete remission, as well as modiﬁcation of
maintenance therapies after HSCT, remain important [24].
Long-term monitoring and early intervention for recurrent
or residual disease continue to be a priority for autologous
HSCT recipients [25]. Although the indications for autologous
transplantation have changed somewhat in recent years,
with less transplantation being performed for AML and
breast cancer, the incidence of nonrelapse deaths due to the
emergence of second cancers, circulatory, and respiratory
diseases continues to increase more than a decade after
autologous HSCT. Our ﬁndings highlight the importance of
long-term follow-up of HSCT recipients at increased risk for
developing potentially fatal health conditions to enable the
development of targeted surveillance, screening, and inter-
vention programs aimed at the early detection and treatment
of these conditions.
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